Kendra Adams
Fortuna: 528 018 $ al 31/08/2026
Fortuna: 528 018 $ al 31/08/2026
Kendra R.
Adams is currently Treasurer, Chief Financial & Accounting Officer at C4 Therapeutics, Inc. since 2026.
Former positions include Director-Investor Relations at ARIAD Pharmaceuticals, Inc. and VP-External Communications & Investor Relations at Agios Pharmaceuticals, Inc. Education includes undergraduate studies at Hamilton College (New York).
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
C4 THERAPEUTICS, INC. 0,12 % | 18/09/2026 | 142.323 ( 0,12 % ) | 528 018 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| C4 THERAPEUTICS, INC. | Director Financiero/CFO | 18/09/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Contacto de Relaciones con Inversores | - |
| ARIAD PHARMACEUTICALS, INC. | Contacto de Relaciones con Inversores | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Hamilton College (New York)
Hamilton College (New York) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.